Lithium Ion

Lithium Ion

SCHEMBL4422535

CCC(S(=O)(=O)[O-])S(=O)(=O)[O-].[Li+].[Li+]

nearest known ligand 0.30

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL29170915 0.94 TP53 (0.30) TP53
SCHEMBL2522158 0.94 TP53 (0.30) TP53
SCHEMBL2749723 0.94 TSHR (0.32) TP53
SCHEMBL2519322 0.94 TP53 (0.30) TP53
SCHEMBL28549412 0.78 TSHR (0.38) TP53
Lithium Ion SCHEMBL5014275 0.78 CA1 (0.36)
Lithium Ion SCHEMBL16756641 0.77 CYP3A4 (0.40)
Lithium Ion SCHEMBL5014269 0.75
Lithium Ion SCHEMBL5016639 0.73
Lithium Ion SCHEMBL5014301 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9118062-B2 Anode and method of manufacturing the same, and battery and method of manufacturing the same SONY CORPORATION (JP) 2015-08-25 US claimed
US-20080311472-A1 ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME SONY CORPORATION (JP) 2008-12-18 US claimed
US-9583789-B2 Non-aqueous electrolyte secondary battery NEC CORPORATION (JP) 2017-02-28 US disclosed
US-9118062-B2 Anode and method of manufacturing the same, and battery and method of manufacturing the same SONY CORPORATION (JP) 2015-08-25 US disclosed
US-20150155597-A1 NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY NEC CORPORATION (JP) 2015-06-04 US disclosed
US-20090169985-A1 ELECTROLYTIC SOLUTION, SECONDARY BATTERY AND METHOD OF MANUFACTURING SAME, AND SULFONE COMPOUND SONY CORPORATION (JP) 2009-07-02 US disclosed
US-20080311472-A1 ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME SONY CORPORATION (JP) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169985-A1 ELECTROLYTIC SOLUTION, SECONDARY BATTERY AND METHOD OF MANUFACTURING SAME, AND SULFONE COMPOUND CA12, CA1, STS TP53 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.